Relay Therapeutics
Brenton Mar currently serves as Senior Vice President and Head of Clinical Development at Relay Therapeutics, leading clinical strategies for innovative cancer therapies, including lirafugratinib and selective PIK3CA inhibitors. Prior to this role, Brenton held the position of Vice President of Clinical Development at Blueprint Medicines, overseeing global clinical strategies for multiple investigational therapies and coordinating with academic and external partners. Brenton's earlier experience includes roles as Senior Medical Director, Medical Director at Boston Children's Hospital, and Instructor at Harvard Medical School, with a focus on pediatric hematological malignancies and precision medicine. Education includes an M.D. and Ph.D. in Medicine with a concentration in Molecular Genetics from the University of Illinois at Chicago, along with a B.S. in Biochemistry from UCLA.
Relay Therapeutics
1 followers
Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology.